Stockscreener 앱 받기
4.51
0.68%
0.07
전일 마감가:
$4.44
열려 있는:
$4.43
하루 거래량:
16,962
Relative Volume:
0.34
시가총액:
$85.11M
수익:
-
순이익/손실:
$-34.17M
주가수익비율:
-1.9925
EPS:
-2.2635
순현금흐름:
$-47.63M
1주 성능:
-2.40%
1개월 성능:
+1.82%
6개월 성능:
+16.41%
1년 성능:
+60.22%
1일 변동 폭
$4.43
$4.54
1주일 범위
$4.28
$4.60
52주 변동 폭
$2.44
$5.12
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.46 | 84.73M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
427.54 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.05 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.49 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.88 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.47 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com Canada
PolyPid says late-stage surgery trial cut severe wound infections 64% - Stock Titan
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026 - RTTNews
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global By Investing.com - Investing.com Australia
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - markets.businessinsider.com
PolyPid to present D-PLEX100 pharmacokinetic data at ESCMID Global - Investing.com
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating - GlobeNewswire
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
In a Phase 3 surgery trial, PolyPid's antibiotic released for 32 days - Stock Titan
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Growth in Short Interest - MarketBeat
PYPD Options Volatility — NASDAQ:PYPD - TradingView
PYPD Options Chain — NASDAQ:PYPD - TradingView
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3%Still a Buy? - MarketBeat
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Can PolyPid (PYPD) Stock Beat Estimates | Price at $4.24, Down 3.42%Aggressive Growth Stocks - Newser
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
2.04%
자본화:
|
볼륨(24시간):